Boston Scientific (NYSE:BSX) Stock Sale Reported by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $50,001 and $100,000 in Boston Scientific stock on September 9th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Stock Down 1.5%

NYSE:BSX traded down $0.66 during trading hours on Tuesday, reaching $43.45. The company’s stock had a trading volume of 2,087,721 shares, compared to its average volume of 18,718,625. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market capitalization of $62.97 billion, a P/E ratio of 17.63, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57. The stock has a 50 day moving average price of $46.97 and a two-hundred day moving average price of $52.24. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $105.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research reports. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a report on Wednesday, July 29th. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Oppenheimer reduced their target price on shares of Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a report on Monday, September 21st. Needham & Company LLC lowered their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Finally, BTIG Research cut their price target on Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research report on Wednesday, September 9th. Twenty-three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $70.19.

Institutional Trading of Boston Scientific

Institutional investors have recently made changes to their positions in the company. Kelleher Financial Advisors purchased a new position in Boston Scientific in the 2nd quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the first quarter worth about $28,000. Rakuten Securities Inc. purchased a new stake in Boston Scientific during the 2nd quarter valued at about $30,000. Cassaday & Co Wealth Management LLC purchased a new stake in Boston Scientific during the 1st quarter valued at about $32,000. Finally, Cetera Trust Company N.A purchased a new position in Boston Scientific in the 2nd quarter worth approximately $32,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Michael Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 194,522 shares of company stock worth $9,385,210 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.